SCHEMBL7103213

SCHEMBL7103213

COC(=O)c1ccc2c(c1)c(=O)n(Cc1ccc(Br)cc1)c(=O)n2C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARG Q86W56 2/20 0.52
MAPK8 P45983 4/20 0.51
MMP13 P45452 1/20 0.51
SLC22A8 Q8TCC7 1/20 0.51
HDAC1 Q13547 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
TP53 P04637 1/20 0.48
ALDH1A1 P00352 2/20 0.47
MAPK10 P53779 1/20 0.47
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
KMT2A Q03164 3/20 0.46
PKM P14618 2/20 0.46
HPGD P15428 2/20 0.46
KDM4E B2RXH2 1/20 0.46
GLA P06280 1/20 0.46
GAA P10253 1/20 0.46
HTT P42858 1/20 0.46
HSD17B10 Q99714 1/20 0.46
PTGS2 P35354 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27588029 0.90 PARG (0.52) PARGMMP13SLC22A8HDAC1TP53
SCHEMBL7634243 0.89 TP53 (0.57) PARGMMP13SLC22A8HDAC1SMN1; SMN2
SCHEMBL27588021 0.89 PARG (0.54) PARGMAPK8MMP13SLC22A8HDAC1
SCHEMBL27588034 0.89 PARG (0.52) PARGMMP13SLC22A8HDAC1SMN1; SMN2
SCHEMBL27588009 0.89 PARG (0.54) PARGMMP13SLC22A8HDAC1SMN1; SMN2
SCHEMBL6245488 0.89 MMP13 (0.60) PARGMAPK8MMP13SLC22A8HDAC1
SCHEMBL27588051 0.88 HDAC1 (0.53) PARGMMP13SLC22A8HDAC1SMN1; SMN2
SCHEMBL7105028 0.88 MMP13 (0.59) PARGMAPK8MMP13SLC22A8HDAC1
SCHEMBL6256249 0.87 MMP13 (0.61) PARGMAPK8MMP13SLC22A8HDAC1
SCHEMBL28750653 0.87 PARG (0.50) PARGMAPK8MMP13SLC22A8HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1537105-A Quinazolines useful as MMP-13 inhibitors ��������ʲ��������ι�˾ 2004-10-13 CN disclosed
EP-1368324-A1 QUINAZOLINES AS MMP-13 INHIBITORS Warner-Lambert Company LLC (US) 2003-12-10 EP disclosed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US disclosed
WO-2002064572-A1 QUINAZOLINES AS MMP-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193377-A1 Quinazolines as MMP-13 inhibitors MMP13, MMP9, MMP3 PARG 3624/4885MAPK8 2793/4885MMP13 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.